Entering a New Paradigm for Biotech and Healthcare Innovators
As 2023 draws to a close, the biotech sector continues to face a challenging landscape: public markets are still on the path to recovery, the IPO window remains narrow and private investors are exercising caution. However, there are reasons for optimism. Market fundamentals remain strong, and there are early signs of stabilization – possibly even improvements. Delivering insights on the current state of the biotech sector, highlighting the strategic implications for both investors and biotech firms, and addressing three central questions:
Alexandra Zemp, Partner, McKinsey
A Complex Path Forward Or A Trail Ahead Full Of Opportunity? The Healthcare Markets In 2023 & Beyond - Expectations, Pressures, & Opportunities
As we are knocking on the door of 2024 and preparing for another year ahead of investments, deals, and acquisitions, 2023 would have seen a total of 5 patent expirations of established biological products worth billions.
Potential innovation deficits must be addressed and new revenues found, while emerging biotechs continue to navigate a capital-constrained environment to meet the next value inflection point. Medtech faces it's own challenges with a drop in M&A dealmaking and capital raised, and pressure on R&D investments, while the broad encompassing healthtech and digital health space has seen continued investment in some areas and declined in others.
A multi-stakeholder panel reviews and explores how they see these challenges and dynamics evolving and how investors, pharma and other key stakeholders see the dynamics evolving through into 2024 and beyond.
Moderator: Eleanor Malone, Editor in Chief, Commercial Pharma Insights, Citeline
A separate ticket is required to attend the 2023 Awards Ceremony. Full details can be found here.
|00:00||Close of European Lifestars Awards And Gala Dinner|